Policy statementIn effectFederal

HHS will not enforce against 503A compounding of six peptides, under ten conditions

On October 30, 2026 HHS published an interim policy: it does not intend to act against state licensed pharmacies or physicians compounding BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500, if every condition is met and only in the listed forms and routes.

Source Oct 30, 2026Briefing Nov 15, 2026Reviewed Nov 15, 2026Next review Feb 15, 2027
01What changed

FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend these six peptides for the 503A bulks list, against the recommendation of FDA's drug center. The Secretary's policy, filed October 28 and published October 30, now says HHS does not intend to take enforcement action against compounding with them until a final rule decides whether each is listed. The notice describes it as a draft interim policy that creates no rights and binds no one.

All ten conditions must be met, including: API from an FDA registered manufacturer with a lot specific certificate of analysis; a single active ingredient; the label "This is a compounded drug product. Not for resale."; MedWatch reporting to FDA and the states involved; an FDA cleared syringe as the only device; documented oral bioavailability for oral forms; and a patient specific prescription. Each peptide is limited to set forms and routes, for example Semax free base intranasal only.

02Who this affects
  • 503A pharmacies compounding or asked to compound any of the six peptides.
  • Telehealth and wellness programs prescribing them.
  • Research use only peptide sellers, whose supply the policy aims to displace.

Federal enforcement only, and only for state licensed 503A pharmacies, federal facilities and licensed physicians. It does not cover 503B outsourcing facilities, does not add any peptide to the 503A bulks list, and does not displace state law or state board positions on peptides.

03Key dates
Source publishedOctober 30, 2026Federal Register notice of availability, FR Doc. 2026-22192; filed October 28.
EffectiveOctober 30, 2026HHS states it does not intend to take enforcement action while the 503A bulks list is developed through rulemaking.
Comment deadlineNovember 13, 2026The notice allows written comments for 2 weeks after publication on docket HHS-OASH-2026-0496.
ExpiresNot statedRuns until each peptide is addressed in a final 503A bulks list rule; HHS may revisit it if a safety signal or quality issue arises.
04Why it matters

This is the first federal opening for compounded peptides, and it is narrow. Outside the six substances, their routes or any one condition, nothing changes, and HHS can revisit it at any time. State notices barring research grade peptides still stand. A pharmacy relying on the policy should be able to show every condition was met for every lot.

05What to do now
  1. Compare each peptide product you make or list against the six substances and their permitted forms and routes; withdraw anything outside them.
  2. Keep certificates of analysis and manufacturer registration records for every lot; confirm labels and MedWatch reporting.
  3. Check the peptide position of each state board where you hold a permit before shipping.
06How this relates to certification

Compounding (503A and 503B). The Compounding domain covers which bulk substances a pharmacy compounds, where they come from and how products are labelled. This policy sets federal conditions on all three for six peptides.

07Sources
All briefingsRevision 2ebe888be508

Know where your pharmacy stands before the rules change again.

Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.

Back to Regulatory Watch